Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation at Clinical Trials at the Summit 2025, scheduled for June 21, 2025, in Las Vegas. The company will deliver multiple presentations focused on their OTX-TKI program, including Phase 1 study results of sustained-release axitinib hydrogel for wet AMD, updates on SOL-1 and SOL-R pivotal Phase 3 trials, and safety and efficacy data from the HELIOS Phase 1 study for diabetic retinopathy. Key company representatives, including CSO Sanjay Nayak and CDO Peter K. Kaiser, will participate in various sessions and panel discussions covering topics from clinical trial results to regulatory guidance and industry innovation. The presentations will showcase Ocular's developments in ophthalmology treatments and their potential impact on patient care.

News Market Reaction – OCUL

+0.23%

1 alert

+0.23% News Effect

On the day this news was published, OCUL gained 0.23%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV.

Clinical Trials at the Summit (CTS) 2025 Presentation Details:

• Company Presentation: Ocular Therapeutix
  Session: Diamond Sponsor Talks
  Presentation Date/Time: Friday, June 20, 2025, 7:55 – 8:05 PM PT
  Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer

• Presentation Title: Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study Results
  Session: Tyrosine Kinase Inhibitors in Clinical Trials
  Presentation Date/Time: Saturday, June 21, 2025, 9:05 – 9:09 AM PT
  Presenter: Patricio G. Schlottmann, MD

• Presentation Title: SOL-1 and SOL-R: Pivotal Phase 3 Trials Evaluating OTX-TKI for Wet AMD
  Session: Tyrosine Kinase Inhibitors in Clinical Trials
  Presentation Date/Time: Saturday, June 21, 2025, 9:09 – 9:13 AM PT
  Presenter: Andrea Gibson, PhD, Senior Vice President, Medical Collaborations

• Presentation Title: Safety and Efficacy of OTX-TKI for Diabetic Retinopathy: HELIOS Phase 1 Study
  Session: Tyrosine Kinase Inhibitors in Clinical Trials
  Presentation Date/Time: Saturday, June 21, 2025, 9:25 – 9:29 AM PT
  Presenter: Dilsher S. Dhoot, MD

• Panel Title: SOL Program Unpacked: Exploring OTX-TKI’s Potential with Trial Experts
  Panel Date/Time: Saturday, June 21, 2025, 9:47 – 10:17 AM PT
  Moderators: Anat Loewenstein, MD, MHA & Daniel F. Martin, MD

• Panel Title: Designing Pivotal Trials Aligned with Evolving Regulatory Guidance
  Panel Date/Time: Saturday, June 21, 2025, 12:45 – 1:05 PM PT
  Panelist: Peter K. Kaiser, MD, Chief Development Officer

• Panel Title: Shifting the Landscape: Can Innovation Truly Change the Paradigm?
  Panel Date/Time: Saturday, June 21, 2025, 5:25 – 5:45 PM PT
  Moderator: Peter K. Kaiser, MD, Chief Development Officer

Exact presentation times may be subject to change.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA™ (also known as OTX-TIC), which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA^® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

What will Ocular Therapeutix (OCUL) present at CTS 2025?

Ocular Therapeutix will present Phase 1 results for OTX-TKI in wet AMD, updates on SOL-1 and SOL-R Phase 3 trials, and HELIOS Phase 1 study results for diabetic retinopathy.

When and where is Ocular Therapeutix presenting at Clinical Trials at the Summit 2025?

The presentations will take place on June 21, 2025, in Las Vegas, with various sessions scheduled throughout the day from 9:05 AM to 5:45 PM PT.

Who are the key presenters from OCUL at the Clinical Trials Summit 2025?

Key presenters include Sanjay Nayak (CSO), Patricio Schlottmann (MD), Andrea Gibson (SVP Medical Collaborations), and Peter K. Kaiser (CDO).

What clinical trials will OCUL discuss at the summit?

OCUL will discuss the US Phase 1 study of OTX-TKI for wet AMD, SOL-1 and SOL-R Phase 3 trials, and the HELIOS Phase 1 study for diabetic retinopathy.